USANA Health Sciences Q1 2025 Earnings Report

USANA Health Sciences EPS Results

• Actual EPS: $0.73
• Consensus EPS: $0.70
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: $0.86

USANA Health Sciences Revenue Results

• Actual Revenue: $249.54 million
• Expected Revenue: $243.08 million
• Beat/Miss: Beat by +$6.46 million
• YoY Revenue Growth: N/A

USANA Health Sciences Announcement Details

• Quarter: Q1 2025
• Date: 4/22/2025
• Time: After Market Closes
• Conference Call Date: Wednesday, April 23, 2025
• Conference Call Time: 11:00AM ET

USANA Health Sciences (NYSE:USNA) develops and sells nutritional supplements, healthy foods and personal-care products. Its offerings include vitamin and mineral supplements, meal-replacement products, protein and nutrition products, and skincare and personal-care items marketed under the USANA brand.

Founded in 1992 by immunologist Myron Wentz, the company uses a direct-selling business model. Products are distributed through independent associates, who market and sell USANA offerings directly to consumers and may build networks of other distributors. The company also provides products through its online shopping platforms in markets where it operates.

USANA serves customers across a range of markets in the Asia-Pacific region, the Americas and Europe. Its products are manufactured and distributed in accordance with applicable regulatory requirements in the jurisdictions where they are sold, with the company emphasizing health, wellness and personal-care solutions.

USANA Health Sciences Q1 2025 Earnings Call Transcript

Key Takeaways

• Net sales grew 12% year-over-year in constant currency for Q1, driven by a 64% sequential increase in net sales and active customers in Mainland China.
• The Hyatt acquisition delivered robust net sales and subscriber growth, with flagship Kitts Daily Greens outperforming expectations and more product launches and channel expansions planned.
• USANA accelerated its new product pipeline with several launches during Q1 and plans to roll out a larger slate of innovations in the second half of the year.
• Management highlighted tariff and trade-policy risks as uncertain but noted no potential impact is currently factored into guidance, and they have built inventory and alternate sourcing to mitigate exposure.
• A measured integration approach is underway to realize operational, supply chain, and IT synergies with Hyatt without distracting from its growth strategy.

Presentation

[Operator]

Greetings. Welcome to the USANA Health Sciences first quarter conference call. At this time, all participants are in a listen-only mode. The question-and-answer session will follow the presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to your host, Andrew Masuda, Director, Investor Relations. Thank you. You may begin.

[Andrew Masuda, Director of Investor Relations at USANA Health Sciences]

Thank you, Diego, and good morning, everyone. We appreciate you joining us to review our first quarter results. Today's conference call is being broadcast live via webcast and can be accessed directly from our website at ir.usana.com. Shortly following the call, a replay will be available on our website. As a reminder, during the course of this conference call, management will make forward-looking statements regarding future events or the future financial performance of our company. Those statements involve risks and uncertainties that could cause actual results to differ, perhaps materially, from the results projected in such forward-looking statements. Examples of these statements include those regarding our strategies and outlook for fiscal year 2025, uncertainty related to the economic and operating environment around the world, and our operations and financial results.

[Andrew Masuda, Director of Investor Relations at USANA Health Sciences]

We caution you that these statements should be considered in conjunction with disclosures, including specific risk factors and financial data contained in our most recent filings with the SEC. I'm joined by our President and CEO, Jim Brown, our Chief Financial Officer, Doug Hekking, our Chief Operating Officer, Walter Noot, our Chief Commercial Officer, Brent Neidig, as well as other executives. Yesterday, after the market closed, we announced our first quarter results and posted our management commentary document on the company's website. We'll now hear brief remarks from Jim before opening the call for questions.

[Jim Brown, President and CEO at USANA Health Sciences]

Thank you, Andrew. Good morning, everyone. USANA is off to a solid start to the year. Our first quarter results were in line with our internal expectations as consolidated net sales grew 12% year over year in constant currency, which includes our first full quarter of contribution from Hiya. Net sales and active customers in our direct selling business grew modestly on a sequential basis for the second consecutive quarter. While consumer sentiment in some of our key markets continues to reflect an overall cautious tone, we're seeing some pockets of strength. For example, sequential first quarter net sales and active customers in our largest market, Mainland China, grew 6% and 4%, respectively. We continue to execute our Associate First strategy that prioritizes associate engagement on multiple levels.

[Jim Brown, President and CEO at USANA Health Sciences]

Accordingly, we held several leadership events across various markets during the quarter and have many events planned throughout the remainder of the year. Early in the second quarter, we hosted our China National Sales Meeting in Nanjing, China. Attendance was strong while we focused on business building, strategy, and training, leadership recognition, and USANA's Associate First commitment. We also used this event to broaden our product offering in China with the introduction of additional products. Both attendees and our executive team came away from this event energized and motivated. We also successfully expanded our product offering in several other markets with the rollout of new products during the first quarter. Simultaneously, the team continued to increase their efforts on several new product launches that are planned to be announced in the second half of the year.

[Jim Brown, President and CEO at USANA Health Sciences]

For instance, Dr. Catherine Armstrong, our Chief Scientific Officer, traveled to several of our Asia-Pacific markets where she met with leaders and our local management teams to gather valuable insights and customer feedback, as well as collaborate on future product ideas. Overall, our direct selling business remains on track to meet the sales guidance range we provided at the beginning of the year. Moving to our newly acquired Hiya business, the team continues to deliver robust results with strong growth in net sales and active monthly subscribers. Hiya continues to see increasing subscriber adoption of both its core product offering as well as new products. For example, Kids Daily Greens, which was launched in the third quarter of 2024, has continued to sell at a higher-than-expected pace.

[Jim Brown, President and CEO at USANA Health Sciences]

We expect this year-over-year growth and Hiya's momentum to continue as the management team executes its plans to launch several new products this year, unveil another strategic partnership, and expand to additional channels. We're confident in the continued growth of the business and are proud to be reaching a new customer demographic in children's health and wellness. Before opening the call for questions, I'd like to provide some thoughts on USANA's position as it relates to tariffs and other trade-related actions by the U.S. and its trading partners around the world. The impact of potential trade policies and tariffs remains highly uncertain at this time. As such, we have not reflected any potential impact in our financial guidance. As a reminder, we manufacture in China for our China market and manufacture for the rest of the world here in the U.S.

[Jim Brown, President and CEO at USANA Health Sciences]

While this structure does afford some insulation from recently enacted tariffs, we do source certain raw materials from various markets around the globe and therefore have exposure to tariffs. Our primary focus for now is on the potential tariff impact associated with importing certain raw materials from China into the U.S. and importing certain raw materials from the U.S. into China. Our team responsible for supply chain management has proactively built inventory the last several quarters to mitigate tariff exposure and has continued to explore alternative sourcing relationships. Our team will continue to evaluate and pursue these strategies to address the potential impact of tariffs and emerging trade policies as they evolve. We plan to provide additional information as we gain greater visibility. With that, I'll now ask the operator to please open the lines for questions.

[Operator]

Thank you. At this time, we will conduct our question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we pull for questions. Our first question comes from Anthony Lebiedzinski with Sidoti & Company. Please state your question.

[Anthony Lebiedzinski, Senior Equity Analyst at Sidoti & Company]

Yes. Good morning, everyone, and thanks for taking the questions. First, China and South Korea did post net sales and active customer count increases on a sequential basis. You guys talked about incentive offerings, helping those out at the start of the year. Just curious as to what your plans are for additional incentives in these countries and elsewhere. How do you guys think about that as far as that's concerned? We'd love to hear your thoughts on that.

[Brent Neidig, Chief Commercial Officer at USANA Health Sciences]

Sure thing. Hey, Anthony, it's Brent here. Good morning.

[Anthony Lebiedzinski, Senior Equity Analyst at Sidoti & Company]

Good morning.

[Brent Neidig, Chief Commercial Officer at USANA Health Sciences]

China did have a good quarter. It was helped at the beginning of the year. We had a couple of product promotions that took place before Chinese New Year, and those were all very, very successful, which helped drive the quarterly results. We're always opportunistic, and we're always looking at promotions, when they're going to make the most sense, how we can drive the best value for our distributors and customers around the world. We are always going to continue to evaluate promotions. Throughout every one of the quarters, the rest of this year, we do have promotional incentives planned. That's currently on the docket. Korea, it also was a good first quarter relative to Q4 of last year.

[Brent Neidig, Chief Commercial Officer at USANA Health Sciences]

I think in both of those markets, we're starting to see some really positive momentum, especially with our event that we had in China during the first part of the second quarter. Really great event that we had there in Nanjing with 13,000 attendees. It's just really strong momentum and great things that we're seeing there.

[Anthony Lebiedzinski, Senior Equity Analyst at Sidoti & Company]

That's encouraging to hear. Yeah. Thanks for that. With respect to Hiya, you talked about the seasonality of the business, which is understandable. As far as the new product launches that are planned for this year, can you share some more specifics about the timing and kind of what's embedded in your guidance?

[Doug Hekking, COO at USANA Health Sciences]

Yeah. They have plans. I think the timing, you'll see that systematically kind of happen over the year. Right now, there's a plan for a pretty meaningful launch of kind of a new relationship at the beginning of May. The team is always bringing different ideas and really is a point to go back and engage a broader funnel and engage more customers in acquiring those customers. This is probably the primary part of their growth strategy right now is on product innovation and broadening that product offering out. You also see them exploring channel opportunities and really kind of evaluating kind of that experience with the customer, which has, I think, been a real strength of theirs. I think we see continuation of that. It really continues to be focused on the children's health and wellness category.

[Doug Hekking, COO at USANA Health Sciences]

That will be squarely in focus as they move forward here. I think there are quite a few opportunities they are encouraged by and some that may play a little bit different, potentially in different channels than what they currently operate.

[Anthony Lebiedzinski, Senior Equity Analyst at Sidoti & Company]

Thanks, Doug. Now that you've had Hiya for four months, do you guys have any updated thoughts on the synergy opportunities?

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

Yeah. I'll tell you, this is Walter. Yes. We've been working with Hiya, especially operationally, because it's one of our strengths. We do manufacturing. We understand supply chain real well, and we can really help them with that. There are definitely synergies. There are a lot of things we're helping with them with IT. Yeah, lots of projects going on right now where both teams are collaborating.

[Jim Brown, President and CEO at USANA Health Sciences]

Yeah. We're taking this very systematic approach. The one thing that we have to be careful with is with a lot of opportunities for synergies, we don't want to overwhelm the Hiya team and somehow distract them from their strategy for 2025 and 2026. We're taking a very measured approach when we're looking at ways to improve them from an operational standpoint. Yeah. I would say many of these things, Anthony, I think the yields and the benefits you're not going to see on an immediacy basis. You'll see that kind of systematically layered in there as we do that. We're really focused on things that will be additive and beneficial to both parties.

[Anthony Lebiedzinski, Senior Equity Analyst at Sidoti & Company]

Got it. That makes sense. Can you give us any update on India, how that's progressing?

[Brent Neidig, Chief Commercial Officer at USANA Health Sciences]

Yeah. India is still a promising market for us. We still have high expectations and high hopes for it to become a very solid, stable market for us in the future. It still is a slow roll, as we've mentioned in previous quarters. Our Chief Sales Officer is over there currently right now, meeting with our leaders and our leadership team over there. We have a lot of energy and emphasis that's being placed on that market to see it start to pick up its growth momentum. We have a few plans in place, and we're optimistic about where it's going to go.

[Anthony Lebiedzinski, Senior Equity Analyst at Sidoti & Company]

Gotcha. Thanks, Brent. Lastly for me, as far as the potential tariff impact, I know you guys brought in some additional inventories to try to get ahead of that. Do you think what you have done so far, is this for one quarter out as far as the higher inventory, or is it more than that? I mean, just trying to obviously, it's still a very fluid and dynamic environment as it relates to tariffs. Just maybe if you could expand on that as far as the level of inventory that you have for raw materials, is it good for how long of a period of time should that be good for?

[Walter Noot, Chief Operating Officer at USANA Health Sciences]

This is Walter. As far as raw material, we've built that up, especially for our nutritional products because that's a lion's share of our revenue. A lot of it comes from there. In February, we started recognizing that there might be tariffs coming, so we bought ahead. The real issue, I mean, it's a little bit of what Jim said earlier. We don't have a ton of inventory coming, for instance, from China to the U.S. It's 6% of our overall raw materials that come from China. We've worked on that for the last four years. The impact isn't as bad, but there's still money there to be made. We wanted to make sure we had inventory ready. We've also been manufacturing finished goods and getting them out to markets, just again, to prepare for tariffs.

[Jim Brown, President and CEO at USANA Health Sciences]

Yeah. Over the last few years, too, Walter and the supply chain team, and we've mentioned this, has really worked on multiple sources. They can come from different geographic locations as well. That has also lessened the impact some.

[Anthony Lebiedzinski, Senior Equity Analyst at Sidoti & Company]

That makes a lot of sense. Thank you very much, guys, and best of luck.

[Jim Brown, President and CEO at USANA Health Sciences]

Thank you.

[Operator]

Thank you. A reminder to the audience, to ask a question, press star one on your telephone keypad. To remove your question, press star two. Our next question comes from Ivan Feinseth with Tigress Financial Partners. Please state your question.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners]

Hi. Congratulations on the great start to the year and the success with the Hiya acquisition. Thanks for taking my question. Just starting with China, what have been some of the new products that were launched there and the reception that you're getting? What do you see as some of the new categories that you're going to be launching?

[Brent Neidig, Chief Commercial Officer at USANA Health Sciences]

Sure thing, Ivan. At our event in the second quarter, the first part of the second quarter there in Nanjing, we only had a couple of new products that were launched. One was a new chewable calcium product for children. That was really well received. It beat our forecast. A couple of other products were launched through our cross-border e-commerce channel. They were some of our existing USANA nutritional products that we were then introducing into China for the first time. Those were also very well received. At the beginning of the year, it is more of a slow roll. As we've talked about in the past, the product introductions and enhancements that are going to take place will accelerate in the back half of the year.

[Brent Neidig, Chief Commercial Officer at USANA Health Sciences]

That is going to be the same for here in the United States and in China and in our other markets around the world. We expect in the second half of the year, you should see a greater acceleration of new product introductions.

[Jim Brown, President and CEO at USANA Health Sciences]

Yeah. As you know from the past, we have our international convention in August. We usually use big meetings like that, like for example, what Brent was talking about in China as launching points. When we talk about the second half, a lot of it will come around that mid-August timeframe.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners]

Okay. For my big question, there are a lot of competing products on the market that contain a lot of bad ingredients. What do you think your opportunity is as RFK starts to implement the elimination of a lot of these colors, dyes, artificial ingredients, and you tend to lean toward a more natural product? How do you feel that the opportunity—how do you feel that that will create an opportunity for you?

[Doug Hekking, COO at USANA Health Sciences]

Yeah. Hi, Ivan. This is Doug. I think we've always been well positioned just from the ethos of the company to capitalize on that. I think one of the things Brent and his team have really done is focused a lot more on gauging the story and telling the differentiation. I think as we continue to perfect that message and get it out there, that resonates at a greater and greater level. Yeah, I think it's an opportunity for us. It's something that we've always done. We've always had that as part of our identity. Having some of those things come to light, I think, provides us the ability to tell a more differentiated story moving forward. Yeah, it actually goes into Hiya as well. They're in the same boat, very clean products. This, again, is an opportunity for both Hiya and USANA.

[Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners]

Thank you. Congratulations again and wish you a great year.

[Doug Hekking, COO at USANA Health Sciences]

Cheers.

[Jim Brown, President and CEO at USANA Health Sciences]

Thanks, Ivan.

[Operator]

Thank you. Once again, to ask a question, press star one on your telephone keypad. To remove yourself from the queue, press star two. We'll pause for another moment while we pull for questions. Thank you. There appears to be no additional questions at this time. I'll hand the floor back to Andrew Masuda for closing remarks.

[Andrew Masuda, Director of Investor Relations at USANA Health Sciences]

Thanks for your questions and participation on today's conference call. If you have any remaining questions, please feel free to contact Investor Relations at 801-954-7210.

[Operator]

Thank you. This concludes today's call. All parties may disconnect. Have a good day.

Participants

Executives

• Doug Hekking, COO
• Walter Noot, Chief Operating Officer
• Jim Brown, President and CEO
• Brent Neidig, Chief Commercial Officer
• Andrew Masuda, Director of Investor Relations

Analysts

• Ivan Feinseth, Chief Investment Officer at Tigress Financial Partners
• Anthony Lebiedzinski, Senior Equity Analyst at Sidoti & Company